We use cookies to ensure that our site works correctly and provides you with the best experience. If you continue using our site without changing your browser settings, we'll assume that you agree to our use of cookies. Find out more about the cookies we use and how to manage them by reading our cookies policy. Hide

Protein-Protein Interactions 2016

Protein Protein Interactions

8 Sep 2016

Virtually all vital cellular processes are controlled by protein-protein interactions (PPIs) including gene expression, proliferation, intracellular communication and apoptosis. Thus, understanding and manipulating PPIs represents a key objective in being able to understand healthy and disease biology. Achieving this goal will lead to probes of cell signalling pathways or, systems biology and next generation molecular therapeutics. However, to date, only a few PPIs have been the subject of a drug discovery initiative by the pharmaceutical industry.

SCI's Fine Chemicals Group in partnership with RSC's BMCS, and in association with PPI-Net, have organised a two day event taking place on 5 and 6 December 2016 at SCI’s headquarter.

Owing to the potential opportunities that being able to modulate PPIs would bring, the past decade has seen this field gain increasing scientific interest, and stimulated significant academic and industrial innovation. This meeting will address recent advances in the characterisation and identification of new PPI inhibitors.

Full programme details will be available nearer the time, but highlights include two plenary talks; Sir Tom Blundell (University of Cambridge, UK) will discuss Cooperativity in multiprotein assemblies over space and time: implications for cell signalling and druggability, while Prof Steve Fesik (Vanderbilt University Medical Centre, USA) will talk about the Discovery of Mcl-1 inhibitors using fragment-based methods and structure-based design.

Additionally, there will be a range of talks on subjects as varied as; in silico assessment of PPI druggability, assay screening technologies for PPIs, structural biology approaches and fragment-based drug design. Speakers from industry and academia will describe strategies for addressing these challenges whilst showcasing the opportunity for creativity and innovation.

The event is designed for scientists at all career levels (students, post-docs, academics, industrialists) engaged in PPI research, alongside those interested in discovering more about this topic. The meeting programme will appeal to chemists, biologists and the wider drug-discovery community.

SCI Members can claim CPD points for attending this conference, and there are opportunities for poster presentations, exhibitions and sponsorship.

The Early Bird deadline for this event is 14 October 2016.

Call for Posters
Late-breaking abstract submission is now open! Anyone wishing to present a poster is encouraged to submit a one-page abstract by Friday 30 September 2016.
Submit your abstract online or email conferences@soci.org directly with 'PPI 2016 – abstract submission' in the subject line. Download an abstract template here.

Exhibition and Sponsorship
Posters and refreshments will be situated in the exhibition area, ensuring excellent access to delegates throughout the meeting. Exhibition places are limited; to book your stand or enquire about sponsorship opportunities, please contact clarice.williams@soci.org for further information and costs.

Conference Dinner
A Conference Dinner will take place on the evening of Monday 5 December. A limited number of tickets are available for GB£60. To book your place, please select this option when registering to attend the event or contact the SCI Conference Team.

Related Links:

Share this article